In vivo electroporation enhances the potency of poly-lactide co-glycolide (PLG) plasmid DNA immunization

Vaccine

Volumn 28, Issue 50, 2010, Pages 7852-7864

  Barbon, Christine M ^a   Baker, Lisa ^a   Lajoie, Christa ^a   Ramstedt, Urban ^a   Hedley, Mary Lynne ^a   Luby, Thomas M ^a  

^a EISAI RESEARCH INSTITUTE   (United States)

Author keywords

Adjuvant; DC; DNA; Electroporation; Endogenous adjuvant; Immunization; Inflammation; Intramuscular; PLG

Indexed keywords

CYTOCHROME P450 1B1; HIGH MOBILITY GROUP B1 PROTEIN; PLASMID DNA; POLYGLACTIN; URIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DNA IMMUNIZATION; DRUG FORMULATION; DRUG POTENCY; ELECTROPORATION; FEMALE; GENE EXPRESSION; IMMUNE RESPONSE; IMMUNOGENICITY; IN VIVO STUDY; MOUSE; NONHUMAN; PHAGOCYTE; PRIORITY JOURNAL; T CELL LYMPHOMA; T LYMPHOCYTE; TH1 CELL;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGEN-PRESENTING CELLS; ARYL HYDROCARBON HYDROXYLASES; CELL LINE, TUMOR; CYTOKINES; ELECTROPORATION; FEMALE; IMMUNITY, INNATE; INJECTIONS, INTRAMUSCULAR; LACTIC ACID; MICE; MICE, INBRED BALB C; MICE, INBRED C3H; MICE, TRANSGENIC; MICROSPHERES; PHAGOCYTES; PLASMIDS; POLYGLYCOLIC ACID; T-LYMPHOCYTES; VACCINES, DNA;

EID: 78650255506     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.09.078     Document Type: Article

References (50)

1. Luby T.M., Cole G.A., Baker L., Kornher J.S., Ramstedt U., Hedley M.L. Repeated immunization with plasmid DNA formulated in poly(lactide-co-glycolide) microparticles is well tolerated and stimulates durable T cell responses to the tumor-associated antigen cytochrome P450 1B1. Clinical Immunology 2004, 112(1):45-53.
2. Roy K., Wang D., Hedley M.L., Barman S.P. Gene delivery with in-situ crosslinking polymer networks generates long-term systemic protein expression. Molecular Therapy 2003, 7(3):401-408.
3. McKeever U., Barman S.P., Hao T., Chambers P., Song S., Lunsford L., et al. Protective immune responses elicited in mice by immunization with formulations of poly(lactide-co-glycolide) microparticles. Vaccine 2002, 20:1524-1531.
4. Hedley M.L., Strominger J.L., Urban R.G. Plasmid DNA encoding targeted naturally processed peptides generates protective cytotoxic T lymphocyte responses in immunized animals. Human Gene Therapy 1998, 9(3):325-332.
5. Maecker D.H., Sherr R.H., Vonderheide M.S., von Bergwelt-Baildon M.S., Hirano N., Anderson K., et al. The shared tumor-associated antigen cytochrome P450 1B1 is recognized by specific cytotoxic T cells. Blood 2003, 102(9):3287-3294.
6. Murray G.I., Taylor M.C., McFadyen M.C.E., McKay J.A., Greenlee W.F., Burke M.D., et al. Tumor-specific expression of cytochrome P450 CYP1B1. Cancer Research 1997, 57:3026-3031.
7. McFadyen M.C.E., Breeman S., Payne S., Stirk C., Miller I.D., Melvin W.T., et al. Immunohistochemical localization of cytochrome P450 CYP1B1 in breast cancer with monoclonal antibodies specific for CYP1B1. Journal of Histochemistry and Cytochemistry 1999, 47:1457-1464.
8. Gribben J.G., Ryan D.P., Boyajian R., Urban R.G., Hedley M.L., Beach K., et al. Unexpected association between induction of immunity to the universal tumor antigen CYP1B1 and response to next therapy. Clinical Cancer Research 2005, 11:4430-4436.
9. Lunsford L., McKeever U., Eckstein V., Hedley M.L. Tissue distribution and persistence in mice of plasmid DNA encapsulated in a PLGA-based microsphere delivery vehicle. The Journal of Drug Targeting 2000, 8:39-50.
10. Newman K.D., Elamanchili P., Kwon G.S., Samuel J. Uptake of poly(d,l-lactic-co-glycolic acid) microspheres by antigen-presenting cells in vivo. Journal Biomedical Material Research 2002, 60:480-486.
11. Randolph G.J., Inaba K., Robbiani D.F., Steinman R.M., Muller W.A. Differention of phagocytic monocytes into lymph node dendritic cells in vivo. Immunity 1999, 11:753-761.
12. Denis-Mize K.S., Dupuis M., Singh M., Woo C., Ugozoli M., O'Hagan D., et al. Mechanisms of increased immunogenicity for DNA-based vaccines adsorbed onto cationic microparticles. Cellular Immunology 2003, 225:12-20.
13. Zhang L., Widera G., Bleecher S., Zaharoff D.A., Mossop B., Rabussay D. Accelerated immune response to DNA vaccines. DNA and Cell Biology 2003, 22(12):815-822.
14. O'Hagan D., Singh M., Ugozzoli M., Wild C., Barnett S., Chen M., et al. Induction of potent immune responses by cationic microparticles with adsorbed human immunodeficiency virus DNA vaccines. Journal of Virology 2001, 75:9037-9043.
15. Widera G., Austin M., Rabussay D., Goldbeck C., Barnett S., Chen M., et al. Increased DNA vaccine delivery and immunogenicity by electroporation in vivo. Journal of Immunology 2002, 164:4635-4640.
16. + T-cell responses. Gene Therapy 2003, 10:717-724.
17. Neumann E., Kakorin S., Toensing K. Principles of membrane electroporation and transport of macromolecules. Methods in Molecular Medicine 2000, 37:1-35.
18. Kadowaki S., Chen Z., Asanuma H., Aizawa C., Kurata T., Tamura S. Protection against influenza virus infection in mice immunized by administration of hemagglutinin-expressing DNAs with electroporation. Vaccine 2000, 18:2779-2788.
19. Selby M., Goldbeck C., Pertile T., Walsh R., Ulmer J. Enhancement of DNA vaccine potency by electroporation in vivo. Journal of Biotechnology 2000, 83:147-152.
20. Dupuis M., Denis-Mize K.S., Woo C., Goldbeck C., Selby M.J., Chen M., et al. Distribution of DNA vaccines determines their immunogenicity after intramuscular injection in mice. Journal of Immunology 2000, 165:2850-2858.
21. Mendiratta S.K., Thai G., Eslahi N.K., Thull N.M., Matar M., Bronte V., et al. Therapeutic tumor immunity induced by polyimmunization with melanoma antigens gp100 and TRP-2. Cancer Research 2001, 61:859-863.
22. + T-cell responses and delays tumor growth in a syngeneic mouse melanoma model. Cancer Research 2002, 62:5489-5494.
23. Otten G., Shaefer M., Doe B., Lui H., Srivastava I., zur Megede J.D., et al. Enhancement of DNA vaccine potency in rhesus macaques by electroporation. Vaccine 2004, 22:2489-2493.
24. Peng B., Zhao Y., Xu L., Xu Y. Electric pulses applied prior to intramuscular DNA vaccination greatly improve the vaccine immunogenicity. Vaccine 2007, 25:2064-2073.
25. Babiuk S., Baca-Estrada M.E., Foldvari M., Storms M., Rabussay D., Widera G., et al. Electroporation improves the efficacy of DNA vaccines in large animals. Vaccine 2002, 20:3399-3408.
26. Vitiello A., Marchesini D., Furze J., Sherman L.A., Chesnut R.W. Analysis of the HLA-restricted influenza-specific cytotoxic T lymphocyte response in transgenic mice carrying a chimeric human-mouse class I major histocompatibility complex. Journal of Experimental Medicine 1991, 173:1007-1015.
27. Mir L.M., Bureau M.F., Gehl J., Rangara R., Rouy D., Caillaud J.M., et al. High-efficiency gene transfer into skeletal muscle mediated by electric pulses. PNAS 1999, 96(8):4262-4267.
28. Tollefsen S., Tjelle T., Schneider J., Harboe M., Wiker H., Hewinson G., et al. Improved cellular and humoral immune responses against Mycobacterium tuberculosis antigens after intramuscular DNA immunisation combined with muscle electroporation. Vaccine 2002, 20:3370-3378.
29. Drabick J.J., Glasspool-Malone J., Somiari S., King A., Malone R.W. Cutaneous transfection and immune responses to intradermal nucleic acid vaccination are significantly enhanced by in vivo electropermeabilization. Molecular Therapy 2001, 249-255.
30. Babiuk S., Baca-Estrada M.E., Foldvari M., Middleton D.M., Rabussay D., Widera G., et al. Increased gene expression and inflammatory cell infiltration caused by electroporation are both important for improving the efficacy of DNA vaccines. Journal of Biotechnology 2004, 110(1):1-10.
31. Shi Y., Rock K. Cell death releases endogenous adjuvants that selectively enhance immune surveillance of particulate antigens. European Journal of Immunology 2002, 32:155-162.
32. Andersson U., Wang H., Palmbald K., Aveberger A.V., Bloom O., Erlandsson-Harris H., et al. High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes. Journal of Experimental Medicine 2000, 192(4):565-570.
33. Rovere-Querini P., Capobianco A., Scaffidi P., Valentinis B., Catalanotti F., Giazzon M., et al. HMGB1 is an endogenous immune adjuvant released by necrotic cells. EMBO Reports 2004, 5(8):825-830.
34. Yang D., Chen Q., Yang H., Tracey K.J., Bustin M., Oppenheim J.J. High mobility group box-1 protein induces the migration and activation of human dendritic cells and acts as an alarmin. Journal of Leukocyte Biology 2007, 81:59-66.
35. Sheets E., Urban R.G., Crum C., Hedley M.L., Politch J., Walker J., et al. Immunotherapy of human cervical high-grade cervical intraepithelial neoplasia with microparticle delivered HPV 16 E7 plasmid DNA. American Journal of Obstetrics and Gynecology 2003, 188(4):916-926.
36. Klencke B., Matijevic M., Urban R.G., Lathey J.L., Hedley M.L., Berry M., et al. Encapsulated plasmid DNA treatment for human papillomavirus 16-associated anal dysplasia: a phase I study of ZYC101. Clinical Cancer Research 2002, 8(5):1028-1037.
37. Garcia F., Petry K.U., Muderspach L., Gold M.A., Braly P.A., Crum C.P., et al. A randomized, multicenter, placebo controlled trial of ZYC101a for the treatment of high grade intraepithelial cervical neoplasia. American Journal of Obstetrics and Gynecology 2004, 103(2):317-326.
38. Hartikka J., Sukhu L., Buchner C., Hazard D., Bozoukova V., Margalith M., et al. Electroporation-facilitated delivery of plasmid DNA in skeletal muscle: plasmid dependence of muscle damage and effect of poloxmer 188. Molecular Therapy 2001, 4:407-415.
39. Hofmann G.A., Dev S.B., Nanda G.S., Rabussay D. Electroporation therapy of solid tumors. Critical Reviews in Therapeutic Drug Carrier Systems 1999, 16(6):523-569.
40. Imler J.L., Hoffmann J.A. Toll receptors in innate immunity. Trends Cell Biology 2001, 11(7):304-311.
41. Henneke P., Takeuchi O., Malley R., Lien E., Ingalls R.R., Freeman M., et al. Cellular activation, phagocytosis, and bacterial activity against group B streptococcus involve parallel myeloid differentiation factor 88-dependent and independent signaling pathways. Journal of Immunology 2002, 169:3970-3977.
42. Pasare C, Medzhitov R. Toll-like receptors: linking innate and adaptive immunity. Microbes and Infection 2004, 6(15):1382-1387.
43. Akira S., Uematsu S., Takeuchi O. Pathogen recognition and innate immunity. Cell 2006, 124(4):783-801.
44. Bianchi M. DAMPs, PAMPs and alarmins: all we need to know about danger. Journal of Leukocyte Biology 2007, 81:1-5.
45. Serhan C.N., Brain S.D., Buckley C.D., Gilroy D.W., Haslett C., O'Neill L.A.J., et al. Resolution of inflammation: state of the art, definitions and terms (review). FASEB Journal 2007, 21:325-332.
46. Shi Y., Evans J.E., Rock K.L. Molecular identification of a danger signal that alerts the immune system to dying cells. Nature 2003, 425:516-521.
47. Heath W.R., Carbone F.R. Immunology: dangerous liaisons. Nature 2003, 425:460-461.
48. Recommendations of the Advisory Committee on Immunization Practices No. RR-4 (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence. MMWR 1993;42.
49. Morrow MP, Yan J, Pankhong P, Shedlock DJ, Lewis MJ, Talbott K, et al. Molecular Therapy 2010 (June), doi:10.1038/mt.2010.118.
50. Clinicaltrials.gov, HVTN-080 Trial (HIV), VGX-3400 Trial (H5N1 influenza); 2010.